QIAGEN N.V.

QIAGEN N.V. is a German-founded multinational provider of "Sample to Insight" solutions, enabling customers to gain valuable molecular insights from biological samples. The company's mission is to improve the quality of life by providing access to genomic and molecular insights. Its corporate headquarters are located in Venlo, Netherlands, with main operative headquarters in Hilden, Germany.

QIAGEN's comprehensive portfolio includes sample technologies for isolating and processing DNA, RNA, and proteins, assay technologies for making biomolecules visible for analysis, bioinformatics solutions for data interpretation, and automation systems to streamline workflows. Key products include the QuantiFERON-TB Gold Plus test for latent tuberculosis, the QIAstat-Dx syndromic testing platform, and the QIAcuity digital PCR system. The company serves a diverse customer base across molecular diagnostics (human healthcare) and life sciences (academia, pharmaceutical R&D, and industrial applications like forensics).

In recent news, QIAGEN reported its preliminary Q1 2026 results and updated its full-year 2026 outlook, citing mixed sales trends, including lower demand for QuantiFERON immigration testing and cautious spending in U.S. Life Sciences. Despite these headwinds, the company continues to launch new solutions, such as the QIAstat-Dx BCID GPF Plus AMR Panel for bloodstream infections, reinforcing its position as a global leader in its specialized markets. Thierry Bernard serves as the company's Chief Executive Officer.